A SIMPLE KEY FOR ABBV-744 BRD4 INHIBITION IN CANCER CELL LINES UNVEILED

In Phase A, members will acquire distinctive doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. More individuals is going to be enrolled on the determined monotherapy dosign regimen. In Section B, participants will acquire oral ruxolitinib and ABBV-744 might be provided as "include-on" therapy. In Phase C, members will